Article: Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial


JAMA internal medicine 2015; 175(5), 691-700.

Article Link: DOI: [10.1001/jamainternmed.2015.0289](https://doi.org/10.1001/jamainternmed.2015.0289)

Review:

Strengths:
- Multi-center – 15 palliative care centers in the United States
- Intention to treat analysis
- Secondary outcomes included financial benefit for patients and quality of life.

Weaknesses:
- 60-day mortality was chosen arbitrarily when life expectancy was up to one year
- McGill QOL questionnaire
- A larger proportion of patients in the discontinuation group were cognitively impaired. This may have effect on the quality of life results.
- Data was not reported for some secondary outcomes, including the numbers for cardiovascular death.

Relevance to Palliative Care:
Reducing the number of pills
Reducing cost of healthcare/financial burden of palliative care